Orion PharmaDHA:ORIONPHARM +1.41%69 Gross Margin % is 42.09% as of Mar. 2026, which is 66% above its 10-year median of 25.32. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 69/100 and a GF Value™ of BDT20.38 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 403 Utilities - Independent Power Producers companies, Orion Pharma ranks better than 57.07% on this metric.
Orion Pharma Ltd gross margin has been in long-term decline. The average rate of decline per year is -1.9%.
The historical rank and industry rank for Orion Pharma's Gross Margin % or its related term are showing as below:
DHA:ORIONPHARM'
s Gross Margin % Range Over the Past 10 Years
Min: 16.37 Med: 25.32 Max: 37.89
Current: 37.89
During the past 12 years, the highestGross Margin % of Orion Pharma was 37.89%. The lowest was 16.37%. And the median was 25.32%.
DHA:ORIONPHARM's Gross Margin % is ranked better than 57.07% of 403
companies
in the Utilities - Independent Power Producers industry
Industry Median: 31.35
vs DHA:ORIONPHARM: 37.89
Orion Pharma had a gross margin of 42.09% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Orion Pharma was -1.90% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Orion Pharma had a gross margin of 42.09% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Orion Pharma Gross Margin % Related Terms
Orion Pharma Gross Margin % Historical Data
* Premium members only.
The historical data trend for Orion Pharma's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: Gross Margin % Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma Gross Margin % vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Orion Pharma's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Orion Pharma (DHA:ORIONPHARM) has a Gross Margin % of 42.09% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Orion Pharma and its competitors. This is 66% above median its historical median of 25.32. Over the past decade, Orion Pharma's Gross Margin % has ranged from 16.37 to 37.89. According to the industry distribution chart, Orion Pharma ranks #173 out of 403 companies in the Utilities - Independent Power Producers industry, placing it in the top 42.9%.
Is Orion Pharma's Gross Margin % too high?
Orion Pharma's current Gross Margin % of 42.09% is 66% above median its 10-year median of 25.32. Over the past 10 years, this metric has ranged from a low of 16.37 to a high of 37.89. The Utilities - Independent Power Producers industry median Gross Margin % is 31.35. Orion Pharma's value of 42.09% is 34.3% above this industry median. Based on the distribution chart, Orion Pharma ranks #173 out of 403 companies in the Utilities - Independent Power Producers industry, which is above the industry midpoint. Overall, Orion Pharma has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Gross Margin % compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #173 out of 403 companies for Gross Margin %. This puts Orion Pharma in the upper half of its industry. The industry median Gross Margin % is 31.35. Orion Pharma's value of 42.09% is 34.3% above this benchmark. Historically, Orion Pharma's own Gross Margin % has ranged from 16.37 to 37.89 over the past decade. While the company's 10-year median is 25.32 vs. the industry median of 31.35, Orion Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for an Utilities - Independent Power Producers company?
The median Gross Margin % among Utilities - Independent Power Producers companies is 31.35, based on 403 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Pharma's current Gross Margin % of 42.09% is 34.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median Gross Margin % is 31.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current Gross Margin % is 42.09%, which is 66% above median its own 10-year median of 25.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.38, compared to a current price of BDT28.80 — trading 41.3% above its estimated fair value. The current Gross Margin % is 42.09%, which is 66% above median its 10-year median of 25.32 and 34.3% above the Utilities - Independent Power Producers industry median of 31.35. Orion Pharma's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Gross Margin % is 42.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT28.80 is trading 41.3% above its estimated GF Value™ of BDT20.38.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Gross Margin %: 42.09% (66% above median its 10-year median of 25.32)
GF Value™: BDT20.38 vs. price of BDT28.80 (41.3% above fair value)
Industry Position: 34.3% above the Utilities - Independent Power Producers median (#173 of 403)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
69GF Score
Get the complete analysis for DHA:ORIONPHARM
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
